Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Mathew

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Diabetes, Obesity & Metabolism|February 7, 2019
Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trialDario Tuccinardi, Olivia M Farr, Jagriti Upadhyay, et al.
Diabetes|July 8, 2016
Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical TrialOlivia M Farr, Jagriti Upadhyay, Anna Gavrieli, et al.
Diabetes, Obesity & Metabolism|July 9, 2019
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapiesOlivia M Farr, Jagriti Upadhyay, Chelsea Rutagengwa, et al.
Nature|August 3, 2022
The challenge of unprecedented floods and droughts in risk managementHeidi Kreibich, Anne F Van Loon, Kai Schröter, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Diabetes, Obesity & Metabolism|February 7, 2019
Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trialDario Tuccinardi, Olivia M Farr, Jagriti Upadhyay, et al.
Diabetes|July 8, 2016
Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical TrialOlivia M Farr, Jagriti Upadhyay, Anna Gavrieli, et al.
Diabetes, Obesity & Metabolism|July 9, 2019
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapiesOlivia M Farr, Jagriti Upadhyay, Chelsea Rutagengwa, et al.
Nature|August 3, 2022
The challenge of unprecedented floods and droughts in risk managementHeidi Kreibich, Anne F Van Loon, Kai Schröter, et al.
Pageof 2